Search

Author/Creator Moore, Kenneth T.

5. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions. (23rd May 2013)

Authors:
Sarich, Troy C.; Peters, Gary; Berkowitz, Scott D.; Misselwitz, Frank; Nessel, Christopher C.; Burton, Paul; Cook‐Bruns, Nancy; Lensing, Anthonie W.A.; Haskell, Lloyd; Perzborn, Elisabeth; Kubitza, Dagmar; Moore, Kenneth T.; Jalota, Sanjay; Weber, Juergen; Pan, Guohua; Sun, Xiang; Westermeier, To...
Journal:
Annals of the New York Academy of Sciences
Issue:
Volume 1291(2013)
Page Start:
42
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. (3rd July 2014)

Authors:
Moore, Kenneth T.; Vaidyanathan, Seema; Natarajan, Jaya; Ariyawansa, Jay; Haskell, Lloyd; Turner, Kenneth C.
Journal:
Journal of clinical pharmacology
Issue:
Volume 54:Number 12(2014:Dec.)
Page Start:
1407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Issue 4 (16th May 2014)

Authors:
Moore, Kenneth T.; Krook, Mark A.; Vaidyanathan, Seema; Sarich, Troy C.; Damaraju, C. V.; Fields, Larry E.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 3:Issue 4(2014:Jul./Aug.)
Page Start:
321
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗